Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

PROFESSOR JONAS BERGH

PROFESSOR JONAS BERGH

Jonas Bergh

Visiting Professor

Jonas Bergh holds the Mimi Althainz' Professorship in Oncology at Karolina Institutet (KI) and is senior consultant Radiumhemmet at the Karolina University Hospital in Stockholm. He was recently appointed Director for the Strategic Research Program in Cancer at KI. Between 2009 and 2010, he was Professor of Breast Oncology at Manchester University. Professor Bergh's research is mainly focused on tailored breast cancer treatment.

As Chair of the Swedish Breast Cancer Group between 1995 and 2016 he conducted trials with new drugs and individually tailored dosing of chemotherapy. Through this group he also participated in the first randomised study showing that five years of tamoxifen treatment is better than the previously recommended two years. He has been involved in showing the additional value of other drugs, in particular chemotherapy, in breast cancer treatment. Professor Bergh has participated in several editorial  boards for scientific journals and acted as an external expert consultant for the Swedish Medical Products Agency.

He is currently acting Chair of the Scientific Advisory Group Oncology-Hematology at the European Medicines Agency (EMA), and has been a member since 2004. He is co-chairman of the Early Breast Cancer Trialists' Collaborative Group and is a member of the consensus panels establishing treatment recommendations for primary and metastatic breast cancer. Jonas Bergh is also a fellow of the Royal College of Physicians in London, a member of the scientific council IARC for WHO, Visiting Professor of Breast Cancer Research, at Oxford University and a member of the Nobel Assembly.